Immuron Limited (AU:IMC) has released an update.
Immuron Limited is set to host a captivating live virtual event to discuss the promising Phase 2 results of its Travelan product and the forthcoming Phase 3 clinical trials. The company’s leadership, including CEO Steven Lydeamore, will present how their proprietary technology is charting a course towards addressing travelers’ diarrhea, a condition affecting 30% to 70% of global travelers. With the potential to tap into a market projected to generate $102M in annual revenues, Immuron stands at the cusp of entering the exclusive list of ASX biotechs in Phase 3 trials.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
